

Creation and Validation of Algorithms to Identify Patients with Moderate-to-Severe Osteoarthritis of the Hip and/or Knee and Inadequate/Intolerable Response to Multiple Pain Medications

Berger A¹, Robinson R², Lu Y¹, Zagar A², Yue A¹, Schepman P³, Bassel M¹, Johnston B², Slim M¹, Thakkar S³, Hartrick C⁴

¹Evidera Inc., Waltham, MA, USA; ²Eli Lilly and Company, Indianapolis, IN, USA; ³Pfizer Inc., New York, NY, USA; ⁴Algosunesis, LLC, USA

BACKGROUND

- Osteoarthritis (OA) is a degenerative joint disease that impacts ~32.5 million US adults:¹
 - It is more common in women than men; for all persons, risk increases with age.²
 - 27.8% of those aged >45 years have radiographic OA of the knee(s) (24.3% of men, 30.1% of women); 27.0%, of the hip(s) (25.7% in men; 26.9% in women).³
- Deleterious impacts of OA are substantial and are experienced disproportionately among those with moderate-to-severe disease and/or with relatively high levels of pain.^{4,5} Quantification of these impacts would help inform development of new therapeutics to alleviate their burden; the approach to such a study is complicated by limitations of existing data sources:
 - Healthcare claims databases provide comprehensive information on use and cost of care but lack information on disease severity/progression and pain levels; conversely, medical records provide clinical detail but lack complete data on use and cost of care.
 - If case-selection algorithms of sufficient reliability can be developed, healthcare claims databases could be used to address these and related questions.

OBJECTIVE

- To determine preliminarily whether case-selection algorithms can be developed for use in electronic healthcare databases to identify with reasonably good accuracy patients with: (1) hip/knee OA; (2) moderate-to-severe OA; and (3) inadequate/intolerable response to ≥2 pain-related medications.

METHODS

Data Source

- Data were obtained from Reliant Medical Group, a large, private, multispecialty group practice (>250 physicians in >20 locations) in central Massachusetts:
 - 62% of patients have commercial insurance and 38% are insured through Medicare and/or Medicaid; 14% are aged ≥65 years.
 - Institutional Review Board approval was obtained before chart abstraction or analyses of electronic health data was undertaken.

Study Population


- 50 adults (i.e., aged ≥18 years), selected at random based on presence of defining characteristics between January 1, 2014 and December 31, 2019.

Defining Characteristic	Selection Criteria	N
Hip/knee OA	≥1 claims with relevant diagnoses	46
Back/other joint pain	≥1 claims with relevant diagnoses AND no diagnoses of hip/knee OA	2
No OA	No diagnoses of OA (and site) AND no receipt of HA/IA steroids AND no hip/knee arthroplasty	2

Abbreviations: HA = hyaluronic acid; IA = intra-articular; OA = osteoarthritis

Case Selection Algorithms

- 40 case-selection algorithms developed based on targeted review of published literature, relevant treatment guidelines, and professional organizations.



Statistical Analysis

- Patients' medical records used to ascertain "true status" with respect to each characteristic of interest.
- Case-selection algorithms then applied, with performance assessed vs. true status in terms of sensitivity analysis, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy:
 - Ability of algorithms to collectively correctly identify those with moderate-to-severe OA with inadequate/intolerable response to pain-related medications (i.e., all three criteria) also assessed.

LIMITATIONS

- Relatively small sample (n=50) from single health system; while promising, additional research required to verify and potentially expand upon algorithm combinations identified herein.
- Information available from patients' medical records was extremely variable and often lacking OA-specific severity scales; clinical experience required to fully interpret available information.

RESULTS

Patient Characteristics

- Most patients were aged ≥65 years, female, and Caucasian; use of pain-related therapies was common.






Chart Review

- Evidence of disease severity limited to descriptive text and unavailable for most patients; levels of pain estimated based on descriptors and numeric (but unnamed) pain scales; most patients had information on reason(s) for changes to therapy.




- 94.0% (n=47) had confirmatory evidence of hip/knee OA in medical records; 94.0% (n=47), of moderate-to-severe disease; and 84.0% (n=42), of inadequate/intolerable response:
 - Most patients (80.0% [n=40]) had evidence of all three characteristics.



Algorithms for Identifying Hip/Knee OA

- Each algorithm resulted in 100% PPV and specificity, respectively; "≥1 outpatient visits resulting in diagnoses of OA of the hip/knee" (algorithm #4) and "≥1 medical encounters resulting in diagnoses of OA of the hip/knee" (#15) had the greatest accuracy and sensitivity.




CONCLUSIONS

- Algorithms based on literature review and expert opinion can identify relevant OA patient subgroups, although those used to identify hip/knee OA are more reliable than those used for disease severity or inadequate/intolerable response to pain-related therapies:
 - Machine learning may improve algorithm performance.


Algorithms for Identifying Moderate-to-Severe OA

- Algorithms with 100% PPV and 100% specificity required presence of: OA-related surgeries (algorithm #1); multiple X-ray examinations (#14); nerve block (#9); multiple opioid prescriptions (#4); receipt of NSAIDs (#5, #6); relatively high OA-related costs (#12); and/or use of mobility aids (#10).
 - Receipt of ≥1 HA/IA steroid injections (algorithm #7) had greatest accuracy and sensitivity.



Algorithms for Identifying Inadequate/Intolerable Response

- "Receipt of nerve block" (algorithm #4) resulted in 96% PPV and 62% accuracy; "receipt of either HA/IA corticosteroid injection or nerve block following receipt of 2 different analgesic classes" (#1) resulted in 100% specificity but identified 0 true positives.



Algorithm Combinations for Identifying All Three Characteristics

- Ability of algorithms to identify patients with all 3 characteristics varied substantially:
 - While several algorithm combinations resulted in estimates of PPV ≥90% and accuracy ≥80%, no single combination identified all patients with these characteristics (range of true positives identified was 0.0% to 82.5%).
 - Combination that identified largest number of true positives also resulted in misclassification of 2 patients.
 - Overall accuracy ranged from 16.0% to 82.0%.

Well-Performing Algorithm Combinations				Poor-Performing Algorithm Combination			
Hip/Knee OA: #4 Severity: #1 Inadequacy: #3		Chart Review		Hip/Knee OA: #4 Severity: #7 Inadequacy: #3		Chart Review	
		Yes	No			Yes	No
Algorithms	Yes	33	2	Algorithms	Yes	32	2
	No	7	8		No	8	8
PPV: 94.3%; NPV: 53.3% Sen: 85.5%; Spec: 80.0% Accuracy: 82.0%				PPV: 94.1%; NPV: 50.0% Sen: 80.0%; Spec: 80.0% Accuracy: 80.0%			
PPV: 0.0%; NPV: 16.7% Sen: 0.0%; Spec: 80.0% Accuracy: 16.0%							

Abbreviations: PPV = positive predictive value; NPV = negative predictive value; Sen = sensitivity; Spec = specificity

- No one algorithm combination could identify all true cases; multiple combinations will likely be required to comprehensively capture cohorts:
 - Pragmatic assessment required that considers trade-offs between increasing number of true positives vs. risk of misclassification of false negatives.
 - Pending this assessment, algorithms of high PPV may prove an efficient tool to enable analyses of large healthcare databases to increase knowledge of these important OA subgroups.

REFERENCES
 1. US Centers for Disease Control and Prevention (CDC). Osteoarthritis (OA). <https://www.cdc.gov/arthritis/basics/osteoarthritis.htm>. Published April 2018. Accessed. 2. Park HR, Im S, Kim H, et al. Validation of algorithms to identify knee osteoarthritis patients in the claims database. *Int J Rheum Dis*. 2019;22(5):890-896.
 3. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. *Arthritis and rheumatism*. 2008;58(1):26-35.
 4. Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. *Br Med Bull*. 2013;105:185-199.
 5. Dominick KL, Ahern FM, Gold CH, Heller DA. Health-related quality of life and health service use among older adults with osteoarthritis. *Arthritis and rheumatism*. 2004;51(3):326-331.

ACKNOWLEDGMENTS

This study was sponsored by Eli Lilly and Company and Pfizer Inc.

